Reinventing aspirin

Perhaps the oldest modern pharmaceutical has been repurposed countless times since its discovery. Most recently, it is recommended to some 60 million people in the USA alone to help reduce their risk of heart attack or stroke. Now, Shiqi Peng, Ming Zhao and colleagues, writing in ACS Nano, explain how nano-sized aspirin-Arg-Gly-Asp-Val particles can be delivered to a thrombus by the target carrier Arg-Gly-Asp-Val tetrapeptide. This new form of aspirin could extend the drug's benefits to people who may not respond to taking the bare drug itself.